SANARIA, INC.

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

SANARIA, INC. is a business in national institute of allergy and infectious diseases based in ROCKVILLE, MD, founded in 2003.

Profile

ABSTRACT
Plasmodium vivax (Pv) malaria is second to P. falciparum (Pf) malaria with regard to global prevalence and
morbidity. Unlike Pf, control and elimination of Pv is complicated by frequent relapses – reactivation of dormant
parasitic forms called hypnozoites that persist in the liver for months to more than a year, that are not
eliminated by standard treatment, and that cause recurrent blood stage infections. Only primaquine and
tafenoquine target hypnozoites, drugs potentially causing life threatening acute hemolytic anemia in those with
G6PD deficiency which affects 8% of people in malaria-endemic regions. Efforts to develop better drugs or a
vaccine are hampered by the inability to propagate blood stages of Pv in vitro. Therefore, generating Pv-
infected mosquitoes for controlled human malaria infection (CHMI) to assess drugs, vaccines, and diagnostics
is reliant on feeding mosquitoes on fresh, Pv-infected blood from Pv patients and is rarely done due to complex
logistics. Absence of a readily available Pv CHMI of consistent quality hampers the development and testing of
interventions against Pv malaria compared to Pf. In our phase II grant, we produced Pv sporozoites (SPZ) of
the Chesson strain by feeding Pv-infected blood from specific pathogen free (SPF) Saimiri boliviensis (Sb)
monkeys to aseptic Anopheles stephensi mosquitoes, and demonstrated that PvSPZ were high

As a business in national institute of allergy and infectious diseases, SANARIA, INC. is listed here with the public details available about it.

ROCKVILLE, MD is where the company is located.

The company is listed at the SBIR/STTR stage of development.

The company reports a headcount in the 11-50 range.

Total disclosed funding stands at about $1M.

Website: sanaria.com